ABL1 and acute lymphoblastic leukemia: Using an unbiased screen, we identify GPR65 as a determinant associated with CAR T-cell as well as blinatumomab engager therapy response in patients with B-ALL and in BCR-ABL–transformed B-ALL cells in an immunocompetent C57BL/6 mouse system.